A small molecule inhibitor against VISTA (CA-170)56 is currently in a Phase I clinical trial (NCT02812875), and our findings may provide biomarkers as well as a stimulus further to investigate VISTA therapeutic blockade in mesothelioma. This evidence concerns the gene VSIR and mesothelioma.